GIP and steatosis: Notably, GLP-1 receptor agonists, as well as dual GLP-1/GIP and GLP-1/glucagon receptor agonists, appear to exert the most comprehensive effects on MASLD, simultaneously improving steatosis, insulin resistance, inflammation, and body weight.